智通财经APP获悉，深交所公告，因赛力斯(09927)在香港市场价格稳定期结束且相应A股上市满10个交易日，根据《深圳证券交易所深港通业务实施办法》 的有关规定，港股通标的证券名单发生调整并自2025年12月01日起生效，调入赛力斯。 | 代码 | 简称 | 调整方向 | | --- | --- | --- | | 09927 | 赛力斯 | 调) | ...

12月1日，深交所发布关于深港通下的港股通标的证券名单调整的公告。因赛力斯（09927）在香港市场 价格稳定期结束且相应A股上市满10个交易日，根据《深圳证券交易所深港通业务实施办法》的有关规 定，港股通标的证券名单发生调整并自2025年12月01日起生效。 MACD金叉信号形成，这些股涨势不错！ ...

Core Viewpoint - The stabilization period for the global offering of Seres (09927) has ended on November 30, 2025, which is 30 days after the deadline for submitting the application for public offering in Hong Kong [1] Summary by Relevant Sections - **Stabilization Actions**: During the stabilization period, the stabilization agent, China International Capital Corporation Hong Kong Securities Limited, and its affiliates took the following actions: (1) An overallotment of 16.2928 million H-shares was made, representing approximately 15.0% of the total shares available for subscription under the global offering, adjusted for the exercise of the over-allotment option but before the exercise of the overallotment right [1] (2) A total of 16.2928 million H-shares were continuously purchased in the market at prices ranging from HKD 109.60 to HKD 131.50 per H-share [1] - **Final Purchase Details**: The last purchase during the stabilization period occurred on November 28, 2025, at a price of HKD 116.30 per H-share [1] - **Overallotment Rights**: The overall coordinator, representing the international underwriters, did not exercise the overallotment rights during the stabilization period, and these rights expired on November 30, 2025 [1]

此外，整体协调人(代表国际包销商)于稳定价格期内并无行使超额配股权，而超额配股权已于2025年11 月30日失效。 智通财经APP讯，赛力斯(09927)发布公告，有关全球发售的稳定价格期已于2025年11月30日(即递交香 港公开发售申请截止日期后第30日)结束。 稳定价格操作人中国国际金融香港证券有限公司、其联属公司或代其行事的任何人士于稳定价格期内采 取的稳定价格行动如下： (1)国际发售中超额分配合共1629.28万股H股，相当于全球发售项下可供认购 的发售股份总数的约15.0%(经计及发售量调整权获部分行使后但于超额配股权获行使前);(2)于稳定价格 期内，于市场上连续购入合共1629.28万股H股，价格介于每股H股109.60港元至131.50港元。于稳定价 格期内，稳定价格操作人、其联属公司或代其行事的任何人士于2025年11月28日于市场上最后一次购 入，价格为每股H股116.30港元。 ...

Core Viewpoint - The stabilization period for the global offering of Seres (09927.HK) has ended on November 30, 2025, as per the Securities and Futures (Stabilizing Prices) Rules in Hong Kong [1] Group 1: Stabilization Actions - During the stabilization period, a total of 16,292,800 H-shares were over-allocated, representing approximately 15.0% of the total shares available for subscription under the global offering [1] - The stabilization agent purchased a total of 16,292,800 H-shares in the market, also equivalent to about 15.0% of the initially available shares for subscription, with prices ranging from HKD 109.60 to HKD 131.50 per share [1] - The last purchase during the stabilization period occurred on November 28, 2025, at a price of HKD 116.30 per share [1] Group 2: Oversubscription Rights - The overall coordinator did not exercise the over-allotment option during the stabilization period, and this option expired on November 30, 2025 [2]

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司對 本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 本公告不得直接或間接於或向美國（包括其領土及屬地、美國任何州以及哥倫比亞特區）發佈、 刊發或派發。本公告並不構成或組成在美國境內或於任何其他司法管轄區購買或認購證券的任 何要約或招攬的一部分。本公告所述證券並無亦不會根據《1933年美國證券法》（經不時修訂） （「美國證券法」）或美國任何州或其他司法管轄區的證券法登記。證券不得在美國境內提呈發 售、出售、質押或以其他方式轉讓，惟獲豁免遵守美國證券法登記規定及符合任何適用的州 證券法則另作別論，或除非符合美國證券法項下的S規例，否則不得在美國境外提呈發售、出 售、質押或以其他方式轉讓。證券不會在美國公開發售。 除本公告另有界定者外，本公告所用詞彙與賽力斯集團股份有限公司（「本公司」）發佈的日期為 2025年10月27日的招股章程（「招股章程」）所界定者具有相同涵義。 根據香港法例第571W章《證券及期貨（穩定價格）規則》第 ...

Core Insights - The article highlights the top and bottom AH premium rates for various stocks as of November 27, with Northeast Electric (00042) leading with a premium rate of 864.29% [1] - The article also lists the stocks with the highest and lowest deviation values, indicating significant discrepancies between A-shares and H-shares [1] AH Premium Rate Rankings - The top three stocks with the highest AH premium rates are: - Northeast Electric (00042): 864.29% - Hongye Futures (03678): 269.82% - Sinopec Oilfield Service (01033): 264.86% [1] - The bottom three stocks with the lowest AH premium rates are: - Ningde Times (03750): -5.40% - China Merchants Bank (03968): -1.65% - Heng Rui Medicine (01276): -0.38% [1] Deviation Value Rankings - The stocks with the highest deviation values are: - Vanke Enterprises (02202): 30.48% - Dazhong Public Utilities (01635): 24.57% - Shandong Xinhua Pharmaceutical (00719): 22.88% [1] - The stocks with the lowest deviation values are: - Sairis (09927): -17.06% - China National Airlines (00753): -13.21% - China Life (02628): -13.18% [1] Additional Insights - The article provides detailed tables showing the premium rates and deviation values for the top and bottom AH stocks, indicating market trends and potential investment opportunities [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Seres Group Co., Ltd. 賽力斯集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9927） 海外監管公告 证券代码：601127 证券简称：赛力斯 公告编号：2025-095 本公告乃根據《香港聯合交易所有限公司證券上市規則》第13.10B條而作出。 茲載列賽力斯集團股份有限公司在上海證券交易所網站刊登的《賽力斯集團股份 有限公司關於參與投資設立的股權投資基金變更基金管理人的公告》，僅供參閱。 承董事會命 賽力斯集團股份有限公司 董事長兼執行董事 張正萍先生 香港，2025年11月21日 於本公告日期，本公司董事為：(i)執行董事張正萍先生、尹先知先生、申薇女士 及張正源先生；(ii)非執行董事張克邦先生、尤崢先生、李瑋先生及周昌玲先生； 及(iii)獨立非執行董事李開國先生、張國林先生、景旭峰先生、黎明先生及魏明 德先生。 赛力斯集团股份有限公司 关于参与投资 ...

Core Viewpoint - The stock price of Sais (Hong Kong stock code 09927.HK) closed at HKD 109.50, reflecting a decline of 4.95%, with a cumulative drop of 16.73% since its listing on November 5, 2025 [1] Group 1: IPO Details - Sais was listed on the Hong Kong Stock Exchange on November 5, 2025, opening below its initial offering price at HKD 128.9 [1] - The total number of shares offered globally was 108,619,000 H-shares, with 10,861,900 shares allocated for the Hong Kong offering and 97,757,100 shares for international offering [1] - The final offer price was set at HKD 131.50, raising a total of HKD 14,283.40 million, with net proceeds amounting to HKD 14,016.41 million after deducting estimated listing expenses of HKD 266.99 million [1] Group 2: Cornerstone Investors - Key cornerstone investors include Chongqing Industry Mother Fund, Linyuan Fund, Huatai Capital Investment, and several others such as New China Asset Management and BESS Broadway [2] - New China Asset Management is primarily owned by New China Life Insurance Co., holding 99.6% directly and indirectly [3] - Other notable investors include Sanhua (Hong Kong), which is wholly owned by Zhejiang Sanhua Intelligent Control Co., and Hichain Logistics HK, ultimately controlled by Jiangsu Haichen Logistics Co. [3]

Core Viewpoint - The recent valuation pullback of Seres (09927) presents a buying opportunity for long-term investors, despite the initial market reaction to its IPO being the largest for a Chinese car company and the largest globally this year [1] Group 1: Company Performance - Seres is a leading luxury new energy vehicle (NEV) manufacturer, with its Aito brand ranking among the top three in the new forces segment, featuring models such as M5, M7, M8, and M9 [1] - The M8 model has an average price exceeding 400,000 yuan, while the M9 exceeds 500,000 yuan, both leading in their price segments [1] - The company has shown strong performance, with a compound annual growth rate (CAGR) of 123.46% in Aito brand sales from 2022 to 2024, driving overall revenue growth at a CAGR of 106.42% [1] - For the first three quarters of 2025, Seres achieved revenue of 110.53 billion yuan and a net profit of 5.31 billion yuan, marking a year-on-year increase of 31.56% [1] Group 2: Strategic Partnerships and Innovations - The success of Seres is attributed to strategic decisions made by its founder, Zhang Xinghai, who has transitioned through various industries, culminating in a partnership with Huawei in 2021 to establish a new business model for high-end NEVs [2] - The collaboration with Huawei has allowed Seres to leverage technological advantages, positioning itself as a benchmark in the NEV industry [2] - The company emphasizes self-research and development, leading in four core technologies, which enhances its product competitiveness [2] Group 3: Market Expansion and Investment - Seres is committed to an overseas expansion strategy, recognizing the high growth potential in the global NEV market, with projections indicating significant penetration rates in China, Europe, and North America by 2030 [3] - The company has attracted diverse capital support, including investments from state-owned enterprises and major investment institutions, enhancing its financial backing [3] - The H-share listing is seen as a strategic move to globalize capital and establish a high-end NEV brand presence internationally [3] Group 4: Long-term Investment Value - Overall, Seres is viewed as a long-term investment opportunity, with its strong position in the high-end NEV market and potential for future growth despite short-term market fluctuations [4]